PRPH

0.05864.72%

ProPhase Labs, Inc. 1Q 2026: Revenue $478K, EPS $(0.43) — 10-Q Summary

TradingView

Jun 30, 2026 at 04:01 PM

I'm LongbridgeAI, I can summarize articles.

ProPhase Labs reported a Q1 2026 net loss of $5.354M and diluted EPS of $(0.43), with revenue dropping 66.6% YoY to $478K due to ceased COVID diagnostics and lower supplement sales. The company deconsolidated diagnostic subsidiaries following Chapter 11 filings. Meanwhile, genomics divisions Nebula and DNA Complete continue DTC operations, while BE-Smart™ secured a U.S. patent and PBIO advances Equivir candidates.

ProPhase Labs, Inc. reported a first-quarter 2026 loss as revenue declined sharply from the year-ago quarter amid operational changes in its diagnostics businesses. Revenue was $478K in Q1 2026, and the company recorded a consolidated net loss of $(5.354M), or diluted loss per share of $(0.43).

Financial Highlights

Revenue: $478K for Q1 2026, down from $1.431M in Q1 2025 (YoY change (66.6%)).
Net income: Net loss of $(5.354M) for continuing operations in Q1 2026; consolidated net loss was $(5.354M) versus consolidated net income of $3.966M in Q1 2025 (prior year included a discontinued gain).
Diluted EPS: $(0.43) for Q1 2026, compared with $1.13 in Q1 2025.

Business Highlights

Revenue and channel shift: The year-over-year revenue decline was driven by lower supplement sales and the cessation of COVID diagnostic services.
Operational restructuring: Diagnostic subsidiaries stopped testing in May 2025, filed Chapter 11, and the labs were deconsolidated; collection and reorganization efforts are ongoing.
Genomics & DTC growth: Nebula and DNA Complete continue to offer direct-to-consumer whole genome sequencing, with plans for retail expansion of FDM and university sales.
Product & IP milestones: BE-Smart™ exceeded a key validation threshold (technical success >95%) and received a U.S. patent; the company plans LDT/RUO commercialization in 2026.
Pipeline & commercialization: PBIO is advancing Equivir candidates, Linebacker programs and expanding TK Supplements® retail presence while pursuing strategic partnerships and commercialization paths.

Original SEC Filing: ProPhase Labs, Inc. [ PRPH ] - 10-Q - Jun. 30, 2026

Disclaimer

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Financial Highlights

Revenue: $478K for Q1 2026, down from $1.431M in Q1 2025 (YoY change (66.6%)).
Net income: Net loss of $(5.354M) for continuing operations in Q1 2026; consolidated net loss was $(5.354M) versus consolidated net income of $3.966M in Q1 2025 (prior year included a discontinued gain).
Diluted EPS: $(0.43) for Q1 2026, compared with $1.13 in Q1 2025.

Business Highlights

Revenue and channel shift: The year-over-year revenue decline was driven by lower supplement sales and the cessation of COVID diagnostic services.
Operational restructuring: Diagnostic subsidiaries stopped testing in May 2025, filed Chapter 11, and the labs were deconsolidated; collection and reorganization efforts are ongoing.
Genomics & DTC growth: Nebula and DNA Complete continue to offer direct-to-consumer whole genome sequencing, with plans for retail expansion of FDM and university sales.
Product & IP milestones: BE-Smart™ exceeded a key validation threshold (technical success >95%) and received a U.S. patent; the company plans LDT/RUO commercialization in 2026.
Pipeline & commercialization: PBIO is advancing Equivir candidates, Linebacker programs and expanding TK Supplements® retail presence while pursuing strategic partnerships and commercialization paths.

Original SEC Filing: ProPhase Labs, Inc. [ PRPH ] - 10-Q - Jun. 30, 2026

Disclaimer

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.